Vyleesi is applied across domains where additional symptomatic support is needed for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The treatment is considered relevant for managing symptoms that create noticeable physiological strain and interfere with daily functioning. It is commonly used when low desire causes marked personal distress or interpersonal difficulty.

Symptomatic Management and Therapeutic Benefit

Vyleesi is used for managing the primary symptoms of HSDD, which may assist with the persistent or complete absence of sexual fantasies, the lack of desire for sexual activity, and reduced responsiveness to erotic cues. This medication is commonly used across conditions presenting with heightened symptoms where the primary issue is the chronic loss of motivation for intimacy. It supports the patient during difficult episodes by contributing to easing the overall emotional burden and frustration.

The use of this treatment is considered relevant for addressing symptoms that have developed over time in women who previously experienced normal desire. By addressing the core symptoms, it may provide supportive relief that assists patients in coping more steadily with the difficult manifestations of HSDD and supports general well-being during symptomatic phases.

---

Condition Categories: Support for Desire Deficiency Vyleesi is applied in scenarios where short-term symptomatic assistance is needed for acquired desire deficiency, and it contributes to improved comfort by easing the overall symptom load.

Official Eligibility and Contraindications

Vyleesi is strictly indicated by regulatory agencies for the treatment of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD).

Use is not indicated in men, postmenopausal women, or patients whose low sexual desire is caused by an underlying medical or psychiatric condition, relationship problems, or the effects of a medication.

Category	Regulatory Status	Restriction Details
Absolute Contraindication	Prohibited Use	Patients with uncontrolled hypertension or known cardiovascular disease must not use Vyleesi.
Age Limitations	Use Not Established	Safety and effectiveness have not been established in pediatric or geriatric patients.
Organ Impairment	Use with Caution	Advised for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or severe hepatic impairment due to increased potential for adverse reactions.
Pregnancy Status	Discontinuation Required	Women who can become pregnant must use effective contraception during treatment and discontinue Vyleesi if pregnancy is suspected.

The medicine is also not indicated to enhance sexual performance. The eligibility profile is defined by these specific inclusion and exclusion criteria based on patient demographics, medical history, and condition causality.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Bremelanotide (Vyleesi) around its effects on gastric motility and specific combination restrictions.

---

Documented Pharmacokinetic Interactions

Bremelanotide is documented to slow gastric emptying, a pharmacokinetic effect that can reduce the rate and extent of absorption of concomitantly administered oral medications. This interaction is most relevant for oral drugs whose efficacy requires a rapid onset of effect (such as Indomethacin) or those dependent on maintaining a specific threshold concentration.

Formal Contraindications and Restrictions

Classification	Restriction Statement
Contraindicated Combination	Co-administration with orally administered naltrexone must be avoided due to the risk of decreased systemic exposure of naltrexone, leading to potential treatment failure.
Timing-Based Restriction	Administration is restricted to no more than one dose within a 24-hour period. This mandatory rule is in place to manage the documented, transient pharmacodynamic effects of the drug on blood pressure.

Population-Specific Considerations

Official labeling notes that increased systemic exposure of Vyleesi is documented in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2). The drug has not been evaluated in individuals with severe hepatic impairment, suggesting a potential for increased exposure in this population as well. The product is not associated with clinically significant interactions with alcohol or the Cytochrome P450 enzyme system.

Vyleesi (bremelanotide) is a synthetic cyclic peptide that acts as a melanocortin receptor (MCR) agonist within the central nervous system. Following subcutaneous administration, the molecule crosses the blood-brain barrier and demonstrates its primary activity through high-affinity agonism at the melanocortin type 4 receptor ( MC4 R).

These MC4 R are substantially expressed in brain regions, including the hypothalamic paraventricular nucleus (PVN), which is crucial for modulating arousal and sexual response pathways. Activation of the post-synaptic MC4 R on hypothalamic neurons initiates an intracellular signaling cascade, leading to the release of excitatory neurotransmitters, notably dopamine and norepinephrine, in key brain circuits. This enhanced dopaminergic signaling modulates the balance of central neurochemical activity. The downstream system-level physiological consequence is the activation of neural pathways associated with sexual motivation and response.

How to Use Vyleesi: Official Administration Guidelines

Vyleesi (bremelanotide) is a prescription medicine administered as a subcutaneous (under the skin) injection using a single-dose autoinjector. Adherence to the official instructions for administration is necessary to ensure correct use of the medicine.

---

Dosing and Timing

The recommended dose is 1.75 mg, administered as needed at least 45 minutes before anticipated sexual activity. The optimal administration time should be determined based on individual experience.

Do not administer more than one dose within 24 hours of the last dose, and it is not recommended to administer more than 8 doses per month.

Administration Procedure

• Preparation: Before injection, visually inspect the solution in the autoinjector. The solution should be clear and colorless or practically colorless, and must be discarded if it is cloudy, discolored, or contains visible particles.
• Injection Site: The injection must be given into the abdomen or the thigh only. The drug is self-administered using the prefilled autoinjector.

Treatment Continuation Review

Treatment with Vyleesi should be discontinued by the healthcare provider if there is no reported improvement in symptoms after 8 weeks of use. This review period serves as a point for evaluating the effectiveness of the treatment.

Research Evidence / Overview of Studies for Vyleesi

This section summarizes the official research that has explored the use of Vyleesi (bremelanotide) according to regulatory and scientific literature. The information describes the types of studies conducted and what their findings indicate, without offering any clinical advice or making claims about individual outcomes.

---

Evidence for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

The core scientific evidence for Vyleesi was studied for consistency across two large, multi-center, Phase 3 randomized, double-blind, placebo-controlled trials. These studies, lasting 24 weeks, are the Randomized, Double-blind, Placebo-controlled Trials and research examined how symptoms evolved over time. Researchers specifically enrolled premenopausal women whose low sexual desire was acquired and generalized.

The studies monitored outcomes describing episodic or acute changes, specifically by measuring sexual desire and the personal distress related to having low desire. This comparative evidence was generated by monitoring these outcomes, where the active substance group was measured against the inactive placebo group. The regulatory evaluation of these studies examined data in which patterns were observed related to changes in desire and distress measurements over the 24-week period. This research provides context but not individual predictions about changes in these two specific areas.

---

Evidence from Longer-Term Studies and Follow-Up Data

To gather information beyond the initial six-month period, participants who completed the primary trials were offered the opportunity to enroll in open-label extension studies that lasted up to 52 weeks. These longer-term observations were monitored to gather data on the continued patient experience. Because this data was derived from settings with varying symptom burdens and lacked a placebo control group, it contributes to the broader evidence landscape, but the certainty remains low compared to the primary 24-week trial data. Long-term effects are not fully established by the highest quality of evidence.

---

Areas of Uncertainty and Ongoing Research

The clinical program for Vyleesi was evaluated in a specific and well-defined population: premenopausal women. There is limited information for long-term outcomes in women outside this age range, and data for certain groups remain insufficient, most notably for postmenopausal women and men. Key research limitation frames include the follow-up durations were limited to 24 weeks for the highest-quality evidence.

Additionally, regulatory bodies have specified that research is ongoing through post-marketing commitments, designed to gather data on exposure during pregnancy and lactation. Existing evidence provides limited insight into these specific situations, and therefore, data for these groups are still emerging.

Key Studies & References Efficacy and safety of bremelanotide for treating hypoactive sexual desire disorder in premenopausal women: results of two phase 3, multicentre, double-blind, placebo-controlled, randomized trials.

Common questions about Vyleesi (FAQ)

---

Q: How long does the effect of a single dose of Vyleesi typically last?

Regulatory documents state that the duration of the drug’s effect on sexual desire is not fully characterized, and patients may determine the optimal timing based on their personal experience. However, the temporary effects Vyleesi has on blood pressure and heart rate usually resolve and return to baseline within 12 hours after administration.

---

Q: Does Vyleesi cause changes in blood pressure or heart rate?

Official product information indicates that Vyleesi transiently increases blood pressure and decreases heart rate after each dose. These changes typically peak within 2 to 4 hours and generally resolve within 12 hours. This is a documented, transient effect described in the official product information.

---

Q: What should a patient do if they experience a severe side effect after using Vyleesi?

Regulatory guidance advises patients to seek medical attention right away if they experience symptoms of severe high blood pressure or a serious allergic reaction, as these are documented risks. In the event of severe side effects, regulatory guidance advises seeking immediate medical attention.

---

Q: Can Vyleesi be used if a person has kidney issues?

According to official labeling, Vyleesi is contraindicated (prohibited) in patients who have severe renal impairment (severe kidney issues). Regulatory documents indicate that there is increased exposure to the drug documented in this patient population, necessitating the restriction.

---

Q: Can women with liver problems safely use Vyleesi?

Official product information states that Vyleesi is not recommended for use in patients with moderate or severe hepatic impairment (moderate to severe liver problems). The official documentation indicates this based on considerations for potential health risks.

---

Q: How quickly is Vyleesi processed by the body?

The drug is processed by the body in a way that its transient effects on vital signs provide a general timeframe for resolution. The temporary changes in blood pressure and heart rate usually return to baseline within 12 hours following the dose.

---

Q: What is the recommended time interval between using Vyleesi doses?

The official labeling provides clear rules for limiting use to minimize potential risks. Patients should not administer more than one dose within 24 hours and should not administer more than 8 doses per month.

---

Q: How does Vyleesi differ from other drugs used for low sexual desire, like flibanserin?

Official information classifies Vyleesi as an on-demand melanocortin receptor agonist administered by injection. This is a distinct pharmacological class and method of use compared to other treatments for the condition, which may be daily oral pills.

---

Q: Does Vyleesi work right away, or does it take time to notice effects?

Vyleesi is designed as an on-demand treatment. Official dosing rules specify that the medicine is administered at least 45 minutes before anticipated sexual activity.

---

Q: Can Vyleesi be used for men with sexual concerns?

The regulatory documents for Vyleesi state that the product is not indicated for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in men.

---

Q: Is Vyleesi approved for women who have gone through menopause?

Official labeling for Vyleesi indicates that the medicine is not indicated for the treatment of HSDD in postmenopausal women.

---

Q: Is it safe to use Vyleesi if I have a history of depression or anxiety?

Vyleesi is not indicated if low sexual desire is caused by a co-existing medical or psychiatric condition. Regulatory guidance states this can include a history of major depressive disorder. The labeling emphasizes that the condition must not be caused by a co-existing medical or psychiatric condition.

---

Q: Can Vyleesi be used with all types of antidepressants?

Vyleesi can cause slow gastric emptying, a process that may affect how the body absorbs certain orally administered medications. Although it does not interact with the CYP450 enzyme system, regulatory information advises discussing all medications with a healthcare provider.

---

Q: What does the research say about the long-term safety of Vyleesi?

The core evidence was gathered during placebo-controlled trials that lasted up to 24 weeks. To collect additional information, participants were offered the option to enroll in open-label extension studies that gathered safety data for up to 52 weeks.

---

Q: Are there foods or drinks, besides alcohol, that are known to interact with Vyleesi?

The regulatory labeling states that Vyleesi’s known interaction profile primarily involves slowing gastric emptying for oral medications. Specific food or beverage interactions, such as with grapefruit juice, are not detailed in the core regulatory warnings.

---

Q: Does Vyleesi interact with birth control pills or devices?

Vyleesi's primary known drug interaction is its ability to slow gastric emptying, which may affect the absorption of certain oral medications, including some oral contraceptives. The official documents state that women who can become pregnant are required to use effective contraception during treatment.

---

Q: Is there any research on Vyleesi's effectiveness in women who have had a hysterectomy?

Vyleesi is indicated for premenopausal women with acquired, generalized HSDD. Research evidence has not specifically focused on the impact of a hysterectomy if the patient remains premenopausal and has the indicated condition.

---

Q: Is Vyleesi considered to be a 'cure' for HSDD (Hypoactive Sexual Desire Disorder)?

Vyleesi is formally classified as an on-demand treatment for the condition. Regulatory guidance requires that treatment be discontinued after 8 weeks if a patient does not report an improvement in symptoms. This information positions the drug as an on-demand therapy rather than a permanent cure.

---

Q: What percentage of women in studies reported a positive experience with Vyleesi?

Regulatory documents state that clinical trials demonstrated Vyleesi increased sexual desire and reduced personal distress related to low desire. Specific percentages of women reporting positive outcomes are described in the clinical trial summaries.

---

Q: Is it possible to use Vyleesi while breastfeeding?

Official labeling states it is not known if Vyleesi passes into breast milk. Regulatory documents state that caution is to be exercised when Vyleesi is administered to a breastfeeding woman, and post-marketing research is ongoing to gather more data on this topic.

---

Q: Can Vyleesi be used for sexual problems caused by medications?

Vyleesi is not indicated for low sexual desire that is caused by the effects of a medication or other drug substance. The condition must be acquired and generalized HSDD that is not attributable to other medical factors.

---

Q: Why is it important to check blood pressure before using Vyleesi?

It is important because Vyleesi is contraindicated (prohibited) in patients with uncontrolled hypertension (high blood pressure) or known cardiovascular disease. This is further supported by the fact that the drug causes a transient increase in blood pressure after each dose.

---

Q: Does Vyleesi work for women who have never experienced sexual desire?

The product is indicated for acquired HSDD, which means the low sexual desire developed in a patient who previously had no problems with sexual desire. It is not indicated for women with lifelong HSDD.

---

Q: What distinguishes Vyleesi from placebo in research studies?

In clinical research, the group using the active substance demonstrated patterns of change in measurements of sexual desire and personal distress related to low desire. These changes were different from those reported by the inactive placebo group.

---

Q: What is the recommended maximum cumulative exposure to Vyleesi over a certain time period?

The official labeling advises no more than 8 doses per month. This limit is established to manage the documented adverse effects, which include focal hyperpigmentation and transient cardiovascular changes.

---

Q: Is Vyleesi linked to any specific risk of developing melanoma?

Official labeling documents the risk of focal hyperpigmentation (skin darkening or discoloration) related to the drug's action on the melanocortin system. The core warnings in the available regulatory documents do not explicitly list melanoma.

How to Store and Dispose of Vyleesi

Official regulatory documents define mandatory conditions for the storage, protection, and disposal of VYLEESI (bremelanotide injection).

Storage Requirements

VYLEESI must be stored at or below 77°F (25°C). The product must be protected from light and explicitly must not be frozen. Prior to use, the solution should be visually inspected; if it appears cloudy, discolored, or contains visible particles, the autoinjector must be discarded.

Handling and Disposal

The single-use autoinjector must be used or thrown away immediately after the clear cap is removed. To ensure safety, VYLEESI and all other medicines must be kept out of the reach of children. The used autoinjector must be disposed of in an approved sharps disposal container immediately following the injection.